INDEX

activities of daily living (ADLs), 181–2
Addenbrookes Cognitive Assessment Revised (ACE-R), 187
addiction liaison services
drug and alcohol problems, 256–7 elements, 258–9
fall-induced fracture, 260–261
general hospitals, 256
older adults, 257–8
screening
alcohol problems, 259–60
drug use problems, 260
substance misuse problems, 257
Advance Care Planning (ACP)
advance decisions, provisions, 6, 7
Lasting Power of Attorney (LPA), 6–7
specific medical treatments, 6
Affordable Care Act, 367
age-segregated or mixed-age treatment, 329
age-sensitive psychosocial treatment
baby boomers, 314–15
characteristics
client functioning, 318–19
coping and social skills, 319
cultural differences, 317–18
flexible, 316–17
gender differences, 317
holistic approach, 319
supportive and nonconfrontational, 316
components
biopsychosocial assessment, 320–321
chronic pain, 323
cognitive impairment or dementia, 324–5
empirically-supported psychosocial interventions, 325–8
psychosocial interventions, 328–9
referrals and care coordination, 325
substance-related disorders, 325
treatment planning, 321–322
late life, 315
psychosocial treatments, 315
substance abuse, 315
alcohol
abuse or dependence, diagnosis, 83–4
amount of drinking, estimation, 76–7, 78, 79
binge drinking
Behavioral Risk Factor Surveillance System (BRFSS) data, 82, 83
definition, 81
demography, 82
spinal cord trauma, 81
demographic correlation
general health status, 86
higher education, 86
income, 86
racial differences, 86–7
epidemiological estimation, 76, 81
latent class analysis (LCA), 151
mental disorder, 151

Substance Use and Older People, First Edition.
Edited by Ilana B. Crome, Li-Tzy Wu, Rahul (Tony) Rao and Peter Crome.
© 2015 John Wiley & Sons, Ltd. Published 2015 by John Wiley & Sons, Ltd.
alcohol abuse
characteristics and treatment, 230, 231–3
clinical samples, 238
elders seeking alcohol treatment, 235
hazardous drinking, prevalence reports, 234–5
NHS Trust Community Alcohol Team data, 234
older adults, 236–8
older women, 236
treatment, 237, 238, 239–41
Veterans Administration (VA) evaluation project, 235
withdrawal, 236
alcohol-drug interactions
CNS-acting medications, 158
comorbidity alcohol risk evaluation tool (CARET), 157–8
cross-sectional survey, 157
health effects, 158
mechanisms, 156
National Council on Patient Information and Education (NCPIE) report, 155–6
National Health and Nutrition Examination Survey data (1999–2002), 157
polypharmacy, 156
problem significance, 156–7
random sample study, 157
alcohol-related dementia, 23
alcohol-related policy development, United States
driving policy questions, 365
legal policies
Affordable Care Act, 367
alcohol price and suicide, 367
behaviour problems, 365–6
drinking and driving laws, 367–8, 369
law, public support, 369
minimally intrusive, 368
reductions in targeted behaviours, 366–7
recommended low-risk alcohol consumption levels, 364
traffic crash risks, 365
alcohol use and misuse, ageing and development
biological hypothesis, 128
differences in use, 125
drinking patterns, sex and WHO region, 124, 125
endogenous and exogenous mechanisms, 127
epidemiological and demographic aspects, 124
gender differences, 126
heavy and risk-full use or misuse, 123–4
heterogeneous process, 128
medicines, concomitant use, 124
morbidity hypothesis, 128
mortality hypothesis, 128
problem drinking, age and onset, 127
research results and community programmes, 124
substance use within people, developments, 126
trajectories, 126–7
alcohol use disorder (AUD), 83–5
Alcohol Use Disorders Identification Test (AUDIT), 182, 199, 200
biomarkers, 199, 201
brief intervention (BI), 207–8
Cut down, Annoyed by criticism, Guilt about drinking, needing Eye-opener (CAGE), 198
Phosphatidyl ethanol (PET), 197–9, 201
question screen, 197–8
Short Michigan Alcoholism Screening Test-Geriatric Version (SMAST-G), 199, 201
symptoms, abuse or dependence, 199
time frame, 198
Alcohol Use Disorders Identification Test (AUDIT), 182, 199, 200
alcohol withdrawal syndrome, 38, 45, 46, 275, 296
benzodiazepines, discontinuation, 46
clinical examination, 45
alcohol withdrawal syndrome (cont’d)
elderly individuals, 46
intake after excessive consumption, 45
opiate, 46
treatment
acamprosate and naltrexone, 276
benzodiazepines (oxazepam, lorazepam), 275
sertraline-naltrexone combination, 276–7
American Public Health Association and National Highway Traffic Safety Administration, 78–9
American Society of Addiction Medicine’s (ASAM) Client Placement Criteria, 322
anti-ageing drugs, 45
anti-tobacco counter-marketing campaigns, 376
Assessing Care Of Vulnerable Elders (ACOVE), 298
Assessment of Underutilization of Medication (AUM) tool, 298
Australian National Health and Medical Research Council high risk criteria, 85
baby boomers (1946 to 1964), 18, 60, 285
chronic medical disorders, 60
marijuana use, 18
substance misuse, ethical and legal aspects
capacity, 21–4
coection, 24
confidentiality, 19–20
informed consent, 20–21
Beers criteria, 298, 309
Behavioral Risk Factor Surveillance System (BRFSS), 76–7, 79, 80, 84, 85–6
benzodiazepines
chronic use, 278–9
discontinuation studies, 279
insomnia, treatment, 279
sleep complaints, 279
binge drinking, 226, 227, 235, 237, 245
Behavioral Risk Factor Surveillance System (BRFSS) data, 82
definition, 81
demography, 82
spinal cord trauma, 81
blood alcohol concentration (BAC), 177
brief intervention (BI)
5As
ADVISE, 207
ARRANGE, 208
ASK, 207
ASSESS, 207–8
ASSIST, 208
FRAMES, 326
Motivational Interviewing (MI), 206–7
Brief Intervention and Treatment for Elders (BRITE), 282, 326 see also brief intervention (BI)
capacity see also The Mental Capacity Act 2005 (MCA)
assessment, 23
clinical capacity evaluation, 21
decisional capacity, elements, 21–2, 22
dementia, alcohol-induced, 23–4
denial, 23
medical and psychiatric conditions, 21
mental capacity legislation, 4
and substance misuse, 3–4
Center for Substance Abuse Treatment (CSAT), 77
Centers for Disease Control and Prevention (CDC) criteria, 79, 116
chronic obstructive pulmonary disease (COPD), 181
Cigarette Labeling and Advertising Act, 373
cigarette neo-prohibitionism, 377
cigarette smoking
adjusted odds ratios (2002 vs. 2011)
adults aged ≥ 65 years, 69–70, 71
aged 45–64 years, 66, 69–70, 71
annual health care and labour costs, 59
census data, 60
current smoking prevalence,
socioeconomic status (2002 vs. 2011)
adults aged ≥ 65 years, 69–70, 71
aged 45–64 years, 66, 67–8
annual health care and labour costs, 59
demographic characteristics, 59
Epidemiologic Transition Theory, 60
evaluation methodology, 61
Global Adult Tobacco Survey (GATS), 59
multiple health conditions, 60
national trend, current smoking prevalence (2002–2011)
current smoking, 65
daily smoking, 65, 66
nondaily smoking, 65, 66
preventable risk behaviours, 60
sociodemographic characteristics, older adults (2002 vs. 2011)
adults aged 45–64 years, 62, 63–4
adults aged ≥ 65 years, 62, 65
tobacco use see tobacco cessation
clinical medicine
ageing, 35
assumed/real physical limitations, 38
Cut down, Annoyed by criticism, Guilt about drinking, needing Eye-opener (CAGE), 37
drug-related mental health/behavioural disorders, 36
healthcare interactions, 36
health effects, substance abuse
chronic, 39
‘Geriatric Giants’ see ‘Geriatric Giants’
identification tools, 47–8
importance, 36–7
issues, 38
misdiagnosis, health professionals, 37
polypharmacy and functional issues, 46
primary care practitioners, 37
professional awareness and service provision, 35
research, 47
secondary care resources, 36
Short Michigan Alcohol Screening Test (SMAST), 37
substance abuse issues, 36–7
symptoms, 37
training and support, 48–9
uncertainty, factors, 37–8
cocaine, 242
coercion
elder abuse, 24
emotional/financial dependence, 24
legally adjudicated incompetence, 24

cognitive behavioural therapy (CBT), 327
cognitive impairment
alcohol consumption, 40
benzodiazepines, 40
cerebral degeneration and eventual dementia, 40
chronic, 41
extrapolation, 40
medications, 39–40
mental, physical and functional consequences, 39
methodological incompatibilities, 41
psychomotor retardation, 42
Community Mental Health Team (CMHT), 345
comorbidity alcohol risk evaluation tool (CARET), 157–8
Comprehensive Geriatric Assessment (CGA), 48, 307–8
alcohol withdrawal, 178
barriers, 176–7
blood alcohol concentration (BAC), 177
British Medical Association, 177
cannabis and stimulant intoxication, 178
case presentations
alcohol and cognitive impairment, 186–7
driving and substance misuse, 184
frequent attender, 185–6
older women and alcohol, 184–5
pain, 187
polysubstance misuse, 185
collateral information, 178–9
high-risk groups, 177
principles
examination, 180–181
functional status, 181–2
history, 179–80
mini mental state examination (MMSE), 183
psychiatric assessment, 183–4
screening, 182–3
problems, 177–8
setting, 176
SUD, diagnostic and statistical manual criteria, 174–5
computerized provider order entry with clinical decision support (CPOE/CDS), 309–10
confidentiality
health care professional’s obligation, 19
primary care settings, 20
privacy regulations, 19, 20
consent
Advance Care Planning (ACP), forms, 6–7
granting permission, 6
informed, 20–21
COPD see chronic obstructive pulmonary disease (COPD)

Cut down, Annoyed by criticism, Guilt about drinking, needing Eye-opener (CAGE), 37, 182, 198, 234–5, 259–60

Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV), 3, 76, 83, 125, 212, 214

Driver and Vehicle Licensing Agency (DVLA), 184

drug abuse
amphetamines, 205
brief intervention (BI), 206–8
chronic pain, 205
illicit and nonmedical, 150
medical and mental health disorders, 204
methadone maintenance patients, 151–2
muscle relaxants, 205
psychopharmacology, 154–5
screening, 205–6
treatment use and outcomes, 243–5

The Drug Abuse Prevention, Treatment and Rehabilitation Act, 19
drug abuse screening tool (DAST), 182, 183, 260

Drug Abuse Warning Network (DAWN), 109, 110, 112, 113, 151, 245
drug–drug interactions
alcohol and anticonvulsants, 45
chronic alcohol misuse, 44
CNS depressant effects, 45
diabetics, 44
everly, 43–4
‘prescribing cascade’, 44
self-medicators, 44
drugs, policy development
policy design and implementation, 359
policy options, 356–9
policy recommendations and guidelines, 357
problem and arguments, 354–5
‘problem drug users’, 353–4
DSM-III-R alcohol abuse/dependence, 237
DSM-IV Axis I mental disorders, 236
e-cigarettes, 377
elder abuse, 21
ageism and ageist practices, 11
alcohol and substance misuse risk factors, 12–13
awareness, professionals, 16
definition, 11
domestic violence and crimes, 12
effects, 14–15
health and care professionals, 15
practitioners and managers, 15
risk factors, 13–14
safeguarding, 12
social services agencies, 12
types, 12

Elder Abuse and Alcohol, WHO review, 14
elderly, substance use disorders
clinical presentations
alcohol dependence, depression, 159–60
alcohol dependence, medical problems, 159
benzodiazepine dependence, anxiety, 160–161
opioid dependence, chronic pain, 160
cognitive impairment, 163–4
co-morbid medical conditions, 161
evaluation, 162–3
medications, 164–5
safety assessment, 164
screening, 161–2

English National Survey of Psychiatric Morbidity (ENSPM), 92
The European Convention of Human Rights (EUCR)
human rights and freedom, 28
Prohibition of Discrimination (Article 14), 29
right of liberty, 28–9
right to respect for private and family life, 29

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 123, 356
European perspective
‘controlled drugs’, UK law, 28
crime, 28
The European Convention of Human Rights (EUCR), 28–9
legal and ethical aspects, 27
penalizing use of drugs, 28
Index

policy making, 31
research and development, 30
service providers, 27
services for elderly, 29–30
stigma, 32
treatment, ethical issues, 32
underprescribing controlled drugs, 32–3
and USA, 31–2

Family Smoking Prevention and Tobacco Control Act, 377
FRAMES, 252, 326

‘Geriatric Giants’, 36, 48
cognitive impairment, 39–41
iatrogenesis, 43–6
instability, falls and immobility, 41–3
urinary incontinence, 43
GET SMART, 356
Global Adult Tobacco Survey (GATS), 59
Guiding Older Adult Lifestyles (GOAL) project, 282

Harmful Interactions: Mixing Alcohol with Medicines (NIAAA), 364
healthcare models and clinical practices
ageing population
frailty, 266
long-term medical conditions (LTCs), 265
National Health Service, 265
care and workforce development, 267–9
community care, 269
service development and provision, 266–7
Health Insurance Portability and Accountability Act (HIPAA), 19, 20
Health Profiles Project, 282
Healthy Living as You Age (HLAYA) study, 283
heavy or high risk drinking, 77, 78, 226, 236

iatrogenesis, 39
alcohol withdrawal syndrome, 45–6
anti-ageing drugs, 45
drug–drug interactions, 43–5
ICD-9 alcohol-related diagnosis, 246
illicit drug, use and disorders
abuse/dependence, 203
brief intervention (BI), 206–8
health implications, 104
older adults, 202

psychiatric setting, 202
survey studies
marijuana and cocaine users, 98–100
race/ethnicity, 100
toxicoLOGY screening, 203–4
treatment-seeking or clinical patients, studies
drug use initiation, age, 103
methadone, 102
racial characteristics, 102–3
uses, 202
Impact, 281
inappropriate prescribing (IP)
alcohol abuse, 296–7
Comprehensive Geriatric Assessment (CGA), 307–8
computerized provider order entry with clinical decision support (CPOE/CDS), 309
definition, 295
dementia, 296
explicit IP criteria, 298–9
implicit IP criteria, 297–8
inappropriate psychotropic use, 296–7
opioids, 297
pharmacist review and intervention, 308
potential prescribing omissions, 299, 304
prescriber education, audit and feedback, 308
STOPP/START criteria, randomized controlled trial, 305, 306
Wernicke/Korsakoff syndrome, 297
independent decision makers, 6
legislation, 8
stipulations, 8, 9
substance misuse, 8
Independent Mental Capacity Advocate (IMCA)
stipulations, 8, 9
substitute decision maker, 8
infectious diseases, screening, 328
informed consent
Anglo-American ethics and law, 20–21
decisional capacity, enhancing, 21
integrated treatment models
development, 344–6
educational interventions, 283–4
Health Profiles Project, 282
Impact, 281
Pathways, 281
integrated treatment models (cont’d)
primary care treatment, 282
Project MATCH, 281
Prospect, 281
research evidence, 346–7
Substance Misuse and Co-morbid Mental Disorder, 342–4
International Classification of Diseases, Tenth Revision (ICD-10), 114–15
International Classification of the Diseases (ICD), 31

Lasting Power of Attorney (LPA)
behaviour, 7
health and welfare decisions, 6
provisions, 7
substitute decisions, 7
latent class analysis (LCA), 151

mean corpuscular volume (MCV), 185
Medication Appropriateness Index (MAI), 297
medication use review (MUR), 308, 310
The Mental Capacity Act 2005 (MCA)
assessment, 5–6
best interest decisions, 8
consent, 6–7, 20–21
independent decision makers, 8–9
principles, 5
safeguard provisions and vulnerable rights enhancement, 4
and unwise decisions, 6
Michigan Alcoholism Screening Test–Geriatric version (MAST–G), 48, 76
mini mental state examination (MMSE), 183
motivational enhancement therapy (MET), 327
motivational interviewing (MI), 206–7, 326

National Center for Health Statistics (NCHS), 109, 114, 115
National Comorbidity Survey-Replication study, 83–4
National Council on Patient Information and Education (NCPIE), 155–6
National Drug Treatment Monitoring System (NDTMS), 92
National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), 92, 93–7, 99, 364, 366
National Health and Nutrition Examination Survey, 157
National Health Interview Survey (NHIS) epidemiology, cigarette smoking, 61
illness and disability, 61
National Household Survey on Drug Abuse (NHSDA), 98–9
National Institute on Aging’s Health and Retirement Study sample, 80
National Institute on Alcohol Abuse and Alcoholism (NIAAA), 77, 92
National Longitudinal Epidemiologic Survey (NLAES), 84
National Survey of American Life (NSAL), 245
National Survey on Drug Use and Health (NSDUH) data, 82–3, 92, 110–111
New Hampshire VA detoxification unit, 236
‘New Ways of Working’, 345
nonbinge drinkers, 233, 237
nonmedical prescription drug use
ageing populations, characteristics, 109–10
benzodiazepines, 117–18
drug poisoning deaths, 114–16
emergency department cases, 112, 113
inappropriate prescribing, 117
misuse, 117
pain and insomnia, 116
race/ethnic and gender distribution, 111
treatment admissions, 113, 114
Norwegian General Practice (NORGEP) Criteria, 298

opioids, treatment
agonist substitution therapy, 277
medical-psychiatric stepped care, 278
methadone maintenance treatment, 277–8
naltrexone and buprenorphine, 278

Pathways, 281
pharmacological treatments
age-specific programmes, 273–4
alcohol, 275–7
benzodiazepines, 278–9
cannabis, 281
low dose, 273
opioids, 277–8
stimulants, 280–281
tobacco, 274–5
phosphatidyl ethanol (PET), 199, 201
polypharmacy, 46, 156
potentially inappropriate medications (PIMs), 295, 296, 299, 304
potential prescribing omissions (PPOs), 299, 304
prescription drugs, misuse, 136
primary care
Alcohol-Related Problems Survey (ARPS), 252
benefit, 252
c-o-morbidities and social context, 252
FRAMES approach, 252
implications, 249–50
misuse, prescribed medication, 251
populations at risk, 250–251
‘pseudo-addiction’, 252
psychoactive prescription medicine misuse, 251
screening, 251–2
Primary Care Research in Substance Abuse and Mental Health for the Elderly (PRISM-E) study, 282–3
Project MATCH, 281, 327
Prospect, 281
PsyclNFO, 123
psychoactive substances, misuse, 141
psychoeducation, 328
Public Health Cigarette Smoking Act, 373
PubMed, 47, 123
pulmonary emphysema, 280
recommendations
clinical presentations, 384–5
education and training, 385
epidemiology, 384
treatment interventions, 386
relapse prevention therapy (RPT), 327–8
Scottish Drugs Forum, 359
screening
alcohol, 197, 259–60
breast cancer, 196
drug abuse, 260
aberrant drug behaviours, 205
older adults, 204–5
urine toxicology testing, 205–6
illicit drugs, 202–4
mental health issues, 197
older adults, 195, 196
Screening of substance misuse, Brief Intervention and Referral to Treatment (SBIRT) practice, 386
SDDCARE project (Senior Drug Dependents and Care Structure Project), 359
second-hand tobacco smoke, 372, 375
self-medication hypothesis, 139
Short Michigan Alcoholism Screening Test-Geriatric Version (SMAST-G), 37, 199, 201, 259
smoke-free movies, 377–8
Southeast London Community Health Survey (SCHS), 92
South London and Maudsley NHS Foundation Trust, 346
START (Screening Tool to Alert to Right Treatment) criteria, 302–3
stimulants, 280–281
STOPP (Screening Tool of Older Persons’ Prescriptions) criteria, 300–302
Substance Abuse and Mental Health Services Administration (SAMHSA), 18, 77, 92, 109, 315
substance misuse/addiction see also The Mental Capacity Act 2005 (MCA)
anxiety disorder and antisocial personality disorder, 151
and capacity, 3–4
clinical settings, 150–151
decision making capacity, 3
latent class analysis (LCA), 151
lifetime disorders, prevalent rates, 152
mental capacity legislation, 3–4
mental disorder, 151
opioid-dependent patients, 152
past-year psychiatric and medical diagnoses, 152
Substance Misuse and Co-morbid Mental Disorder (SMCD)
care for substance misuse and mental disorders, 341
comprehensive assessment, 343
integrated treatment models, 342–7
service implications, 342
substances abuse
alcohol, 153–4
benzodiazepines and sedative-hypnotics (SH), 154–5
substances abuse (cont’d)
cannabis, 155
cocaine, 155
dopamine (DA), 152–3
opioids/opiates, 154
substance use progression process see also elderly, substance use disorders
access, 135–6
advances in medicine, 134
alcohol use, 133
cross-sectional surveys, 142–3
environmental influences, 140–141
individual factors
eyear-onset abusers, 138
heritable factors, 138
influences, 137
late-onset abusers, 138
pharmacokinetic/dynamic changes, 138
prescribed medications, 138–9
self-medication hypothesis, 139
multiple substances, use, 136–7
prescription drugs, misuse, 136
psychoactive substance use spectrum, 133, 134
regular use, 136
severe consequences, 136
substance properties
miscommunication, 141
policies and norms, 140–141
prescribing practices, 141
psychoactive substances, misuse, 141
symptoms, 142

physician-delivered interventions, 217–18
programmes, 376
service use and characteristics
health conditions, 229–30
National Ambulatory Medical Care Survey data (2001–2012), 229
older adults, 225, 277–8
telephone quit-lines, 218
tobacco, policy development
anti-tobacco counter-marketing campaigns, 376
anti-tobacco proposals
-cigarette neo-prohibitionism, 377
harm reduction, 377
product modification and ‘safer’ cigarettes, 376–7
smoke-free movies, 377–8
legal approach, 373–4
past and present approaches, reduced consumption, 372–3
policy proposals, reduced tobacco prevalence, 378
regulatory and tobacco tax approaches
second-hand tobacco smoke restrictions, 375
tobacco taxes, 374–5
tobacco warning labels, 375–6
Treatment Episode Data Set (TEDS), 18, 84–5, 101–2, 109, 150–151, 238, 239–41, 242–6

urinary incontinence
alcohol, 43
benzodiazepines, 43
description, 43
opioids, 43
US Census Bureau’s 2011 American Community Survey, 79
US National Institute on Alcohol Abuse and Alcoholism (NIAAA), 364
Veterans Administration (VA) evaluation project, 235
VINTAGE, international projects, 284
Wernicke/Korsakoff syndrome, 297